1. Haga S, Yamamoto N, Nakai-Murakami C, Osawa Y, Tokunaga K, Sata T, et al.. "Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry" . Proc Natl Acad Sci U S A. 2008Jun3; 105(22):7809-14. doi: DOI: 10.1073/pnas.0711241105. Epub 2008 May 19. PMID: 18490652; PMCID: PMC2409424.

2. Neurath MF. "COVID-19 and immunomodulation in IBD" . Gut. 2020Jul; 69(7):1335-1342. doi: DOI: 10.1136/gutjnl-2020-321269. Epub 2020 Apr 17. PMID: 32303609; PMCID: PMC7211083.

3. Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. "Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality" . Int J Antimicrob Agents. 2020May; 55(5):105954. doi: DOI: 10.1016/j.ijantimicag.2020.105954. Epub 2020 Mar 29. PMID: 32234467; PMCID: PMC7118634.

4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al.. "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China" . Lancet. 2020Feb15; 395(10223):497-506. doi: DOI: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum in: Lancet. 2020 Jan 30;: PMID: 31986264; PMCID: PMC7159299.

5. Lythgoe MP, Middleton P. "Ongoing Clinical Trials for the Management of the COVID-19 Pandemic" . Trends Pharmacol Sci. 2020Jun; 41(6):363-382. doi: DOI: 10.1016/j.tips.2020.03.006. Epub 2020 Apr 9. PMID: 32291112; PMCID: PMC7144665.

6. Robinson PC, Liew DFL, Liew JW, Monaco C, Richards D, Shivakumar S, et al.. "The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19" . Med (N Y). 2020Dec18; 1(1):90-102. doi: DOI: 10.1016/j.medj.2020.11.005. Epub 2020 Dec 3. PMID: 33294881; PMCID: PMC7713589.

7. Sarzi-Puttini P, Ceribelli A, Marotto D, Batticciotto A, Atzeni F. "Systemic rheumatic diseases: From biological agents to small molecules" . Autoimmun Rev. 2019Jun; 18(6):583-592. doi: DOI: 10.1016/j.autrev.2018.12.009. Epub 2019 Apr 5. PMID: 30959214.

8. Fernández-Ruiz M, Meije Y, Manuel O, Akan H, Carratalà J, Aguado JM, et al.. "ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Introduction)" . Clin Microbiol Infect. 2018Jun;24 Suppl 2:S2-S9. doi: DOI: 10.1016/j.cmi.2018.01.029. Epub 2018 Feb 7. PMID: 29427801.

9. Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, et al.. "Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions" . Autoimmun Rev. 2020Jul; 19(7):102567. doi: DOI: 10.1016/j.autrev.2020.102567. Epub 2020 May 4. PMID: 32376392; PMCID: PMC7196557.

10. Feldmann M, Maini RN, Woody JN, Holgate ST, Winter G, Rowland M, et al.. "Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed" . Lancet. 2020May2; 395(10234):1407-1409. doi: DOI: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9. PMID: 32278362; PMCID: PMC7158940.

11. National Institutes of Health. "Coronavirus Disease 2019 (COVID-19)" . Treatment Guidelines. https://covid19treatmentguidelines.nih.gov/ (Accessed on April 21, 2021)

12. Atzeni F, Masala IF, Rodríguez-Carrio J, Ríos-Garcés R, Gerratana E, La Corte L, et al.. "The Rheumatology Drugs for COVID-19 Management: Which and When?" J Clin Med. 2021Feb16; 10(4):783. doi: DOI: 10.3390/jcm10040783. PMID: 33669218; PMCID: PMC7919806.

13. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al.. "Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" . Ann Rheum Dis. 2020Jul; 79(7):859-866. doi: DOI: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29. PMID: 32471903; PMCID: PMC7299648

14. "The guidelines published by the Turkish Ministry of Health's Scientific Committee" . URL: https://covid19.saglik.gov.tr/Eklenti/39551/0/COVID-19rehberigenelbilgilerepidemiyolojivetanipdf.pdf

15. Wang Q, Liu J, Shao R, Han X, Su C, Lu W. "Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis" . Rheumatol Int. 2021May; 41(5):851-861. doi: DOI: 10.1007/s00296-021-04803-9. Epub 2021 Mar 9. PMID: 33687528; PMCID: PMC7941871.

16. Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al.. "Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry" . Gastroenterology. 2020Aug; 159(2):481-491. e3. doi: DOI: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18. PMID: 32425234; PMCID: PMC7233252.

17. Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, et al.. "Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study" . J Allergy Clin Immunol. 2021Jan; 147(1):60-71. doi: DOI: 10.1016/j.jaci.2020.10.007. Epub 2020 Oct 16. PMID: 33075408; PMCID: PMC7566694.

18. Winthrop KL, Brunton AE, Beekmann S, Polgreen P, Baddley J, Saag KG, et al.. "COVID-19 Study Team. SARS CoV-2 infection among patients using immunomodulatory therapies" . Ann Rheum Dis. 2021Feb; 80(2):269-271. doi: DOI: 10.1136/annrheumdis-2020-218580. Epub 2020 Aug 5. PMID: 32759259.

19. Yousaf A, Gayam S, Feldman S, Zinn Z, Kolodney M. "Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study" . J Am Acad Dermatol. 2021Jan; 84(1):70-75. doi: DOI: 10.1016/j.jaad.2020.09.009. Epub 2020 Sep 11. PMID: 32926977; PMCID: PMC7484805.

20. Haberman RH, Castillo R, Chen A, Yan D, Ramirez D, Sekar V, et al.. "COVID-19 in Patients With Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes" . Arthritis Rheumatol. 2020Dec; 72(12):1981-1989. doi: DOI: 10.1002/art.41456. Epub 2020 Oct 25. PMID: 32725762; PMCID: PMC7722024

21. Scirè CA, Carrara G, Zanetti A, Landolfi G, Chighizola C, Alunno A, et al.. "COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19)" . Clin Exp Rheumatol. 2020Jul-Aug; 38(4):748-753. Epub 2020 Jul 28. PMID: 32723435.

22. Duret PM, Sebbag E, Mallick A, Gravier S, Spielmann L, Messer L. "Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept" . Ann Rheum Dis. 2020Sep; 79(9):1251-1252. doi: DOI: 10.1136/annrheumdis-2020-217362. Epub 2020 Apr 30. PMID: 32354772; PMCID: PMC7456545.

23. Brito CA, Paiva JG, Pimentel FN, Guimarães RS, Moreira MR. "COVID-19 in patients with rheumatological diseases treated with anti-TNF" . Ann Rheum Dis. 2021May; 80(5):e62. doi: DOI: 10.1136/annrheumdis-2020-218171. Epub 2020 Jun 16. PMID: 32546603.

24. Sharmeen S, Elghawy A, Zarlasht F, Yao Q. "COVID-19 in rheumatic disease patients on immunosuppressive agents" . Semin Arthritis Rheum. 2020Aug; 50(4):680-686. doi: DOI: 10.1016/j.semarthrit.2020.05.010. Epub 2020 May 23. PMID: 32512263; PMCID: PMC7245236.

25. Farrokhpour M, Rezaie N, Moradi N, Ghaffari Rad F, Izadi S, Azimi M, et al.. "Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit" . Arch Iran Med. 2021Feb1; 24(2):139-143. doi: DOI: 10.34172/aim.2021.22. PMID: 33636983.

26. Dolinger MT, Person H, Smith R, Jarchin L, Pittman N, Dubinsky MC, et al.. "J. Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab" . J Pediatr Gastroenterol Nutr. 2020Aug; 71(2):153-155. doi: DOI: 10.1097/MPG.0000000000002809. PMID: 32452979; PMCID: PMC7268863.

27. Vechi HT, Maia LR, Alves MDM, Rodrigues-Neto JF. "Favorable outcome of COVID-19 in a young woman with severe Crohn's disease on regular use of adalimumab and prednisone: a case report" . Rev Inst Med Trop Sao Paulo. 2020Dec18; 62:e102. doi: DOI: 10.1590/S1678-9946202062102. PMID: 33331521; PMCID: PMC7748034.

28. The guidelines published by the Turkish Ministry of Health's Scientific Committee https://covid19.saglik.gov.tr/Eklenti/37695/0/COVID-19-hastalarindadestektedavi2-anti-sitokinveantiinflamatuartedavi-koagulopatiyonetimipdf.pdf

29. Alunno A, Najm A, Machado PM, Bertheussen H, Burmester GR, Carubbi F, et al.. "EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19" . Ann Rheum Dis. 2021Feb5; 80(6):698-706. doi: DOI: 10.1136/annrheumdis-2020-219724. Epub ahead of print. PMID: 33547062; PMCID: PMC7871226.

30. Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al.. "Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia" . N Engl J Med. 2021Apr22; 384(16):1503-1516. doi: DOI: 10.1056/NEJMoa2028700. Epub 2021 Feb 25. PMID: 33631066; PMCID: PMC7953459.

31. CORIMUNO-19 Collaborative group. "Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNOANA-1): a randomised controlled trial" . Lancet Respir Med. 2021Mar; 9(3):295-304. doi: DOI: 10.1016/S2213-2600(20)30556-7. Epub 2021 Jan 22. PMID: 33493450; PMCID: PMC7825875.

32. Sparks JA, Wallace ZS, Seet AM, Gianfrancesco MA, Izadi Z, Hyrich KL, et al.. "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry" . Ann Rheum Dis. 2021Sep; 80(9):1137-1146. doi: DOI: 10.1136/annrheumdis-2021-220418. Epub 2021 May 28. PMID: 34049860; PMCID: PMC8172266.

33. Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, et al.. "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry" . Ann Rheum Dis. 2021Jul; 80(7):930-942. doi: DOI: 10.1136/annrheumdis-2020-219498. Epub 2021 Jan 27. PMID: 33504483; PMCID: PMC7843211.

34. Bachiller-Corral J, Boteanu A, Garcia-Villanueva MJ, de la Puente C, Revenga M, Diaz-Miguel MC, et al.. "Risk of Severe COVID-19 Infection in Patients With Inflammatory Rheumatic Diseases" . J Rheumatol. 2021Jul; 48(7):1098-1102. doi: DOI: 10.3899/jrheum.200755. Epub 2021 Mar 15. PMID: 33722949.

35. Ferri C, Giuggioli D, Raimondo V, L'Andolina M, Tavoni A, Cecchetti R, et al.. "COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series" . Clin Rheumatol. 2020Nov; 39(11):3195-3204. doi: DOI: 10.1007/s10067-020-05334-7. Epub 2020 Aug 27. PMID: 32852623; PMCID: PMC7450255.